Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC

Dr. Overman on Investigational Targeted Therapies in mCRCПодробнее

Dr. Overman Discusses ReDOS Study in mCRCПодробнее

Improving Molecular Understandings of mCRCПодробнее

Impact of molecular subsets in colorectal cancer on adjuvant and advanced disease therapyПодробнее

Dr. Overman on Implications of Tumor Location Data for Patients With mCRCПодробнее

Dr. Overman on Next Steps With Immunotherapy in mCRCПодробнее

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRCПодробнее

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRCПодробнее

Dr. Overman on Molecular Subtypes in CRCПодробнее

Molecular Analysis of CTCsПодробнее

T Makushok: Role of molecular motors & MT-binding proteins in cell polarity/regeneration of Stentor.Подробнее

Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI H mCRCПодробнее

Dr. Overman on Distinctions Between Regorafenib and TAS-102 in CRCПодробнее

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRCПодробнее

Integrating molecular data into the diagnosis of CNS tumors: Strategies and perspectivesПодробнее

Molecular Tools in Diagnosis, Prognosis and Treatment – Integrating High Throughput Analysis to DefiПодробнее

Dr. Overman on Unmet Needs With Immunotherapy in mCRCПодробнее

Next-Generation Sequencing and Molecular Subsets in Metastatic Colorectal CancerПодробнее

Dr. Overman on Potential Applications of ctDNA in Colorectal CancerПодробнее